This disrupts the translation initiation complex and provides degradative enzymes with access to the 5′ cap and remaining RNA body. The intimate relationship between mRNA decay and translation ...

Imagine a cancer treatment that precisely targets malignant cells, leaving healthy ones untouched. Consider, also, a cancer treatment that corrects abnormal protein synthesis to produce healthy ...

Imagine a breakthrough in cancer treatment where only malignant cells are targeted, sparing healthy host cells; or patients with abnormal protein synthesis are treated to produce a healthy protein.

No tRNAs recognize these codons. Thus, in the place of these tRNAs, one of several proteins, called release factors, binds and facilitates release of the mRNA from the ribosome and subsequent ...

During translation, multiple ribosomes travel along the nucleic acid chain to build polypeptides that become functional proteins. Occasionally, these molecular decoders pause on the mRNA, either ...

The mRNA cap structure is an important point of consideration for the immunogenicity of your mRNA-based product. Whereas legacy cap analogs produce a Cap0 structure and are recognized by the immune ...

This detection scheme ensures that mRNA that is cap-less, tail-less, or fragmented will not be detected, enabling a measurement of only the fully intact mRNA in a single assay. The kit is provided ...

According to the terms of the agreement, TriLink will supply its patented CleanCap® M6, CleanCap® AG 3’OMe, CleanCap® AG, and CleanCap® AU cap analogs for use in Aldevron’s mRNA ...